EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Gut Microbiome dysbiosis and immune activation correlate with somatic and neuropsychiatric symptoms in COVID-19 patients

Paula L Scalzo, Austin G Marshall, Sirena Soriano, Kristen Curry, Mario Dulay, Timea Hodics, Eamonn M M Quigley, Todd J Treangen, María M Piskorz, Sonia Villapol iD

Journal of Translational Medicine · 14.03.2025 · 23 (1)

DOI: 10.1186/s12967-025-06348-y ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Translational Medicine, online erschienen am 14.03.2025. Verfasst von Paula L Scalzo und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Houston Methodist Research Institute, Houston, TX, USA. Hauptthemen laut MEDLINE: COVID-19, Dysbiosis, Gastrointestinal Microbiome. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 102 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, NINDS NIH HHS, NLM NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Infection with SARS-CoV-2, the virus responsible for COVID-19, can lead to a range of physical symptoms and mental health challenges, including stress, anxiety, and depression. These effects are particularly pronounced in hospitalized patients, likely due to the virus’s direct and indirect impact on the nervous system. Gut dysbiosis, an imbalance in the gut microbiome, has been implicated in immune dysfunction and chronic inflammation in COVID-19 patients. However, the interactions between gut microbiome composition and the physical and mental symptoms of COVID-19 remain incompletely understood.

Methods

We investigated the association between physical and mental symptoms, cytokine profiles, and gut microbiota composition in 124 hospitalized COVID-19 patients. We collected data on demographics, COVID-19 severity, and mental health indicators (stress, anxiety, and depression). Gut microbiome profiling was performed using full-length 16 S rRNA gene sequencing to evaluate microbial diversity and composition.

Results

COVID-19 severity was categorized as low (27.4%), moderate (29.8%), or critical (42.8%). Common symptoms included fever (66.1%) and cough (55.6%), while somatic symptoms (27.3%), anxiety (27.3%), depressive symptoms (39%), and stress (80.5%) were frequently self-reported. Elevated interleukin-6 levels in severe cases highlighted systemic inflammation, reduced gut bacterial diversity, particularly among women and obese patients, correlated with higher disease severity. Notably, the genus Mitsuokella was associated with increased physical symptoms and mental distress, while Granulicatella was linked to critical illness.

Conclusions

Our findings reveal significant associations between mental health status, systemic inflammation, and gut dysbiosis in hospitalized COVID-19 patients. These results indicate the potential for microbiome-targeted therapies to mitigate psychological and physical complications and improve recovery outcomes in this population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19DysbiosisGastrointestinal MicrobiomeHumansFemaleMaleMiddle AgedAdultSARS-CoV-2AgedAnxietyDepressionCytokines

Stichwörter der Autor:innen

AnxietyCOVID-19CytokinesDepressionGut dysbiosisGut microbiomeInflammationMental healthMicrobiome-targeted therapiesSARS-CoV-2

Substanzen

Cytokines

Autor:innen und Institutionen

  • Department of Neurosurgery, Houston Methodist Research Institute, Houston, TX, USA.
  • Center for Neuroregeneration, Houston Methodist Research Institute, Houston, TX, USA.
  • Department of Morphology, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte, Brazil.
  • Department of Computer Science, Rice University, Houston, TX, USA.
  • Department of Computational Biology, Institut Pasteur, Université Paris Cité, Paris, France.
  • Lynda K. and David M. Underwood Center for Digestive Health, Houston Methodist Hospital, Houston, TX, USA.

ORCID-Profile: Sonia Villapol

Förderung

  • NIA NIH HHS
  • NINDS NIH HHS
  • NLM NIH HHS
  • Gulf Coast Consortia
  • National Institute of Neurological Disorders and Stroke
  • National Institute on Aging

Zitieren

APA

Scalzo, P. L., Marshall, A. G., Soriano, S., Curry, K., Dulay, M., Hodics, T., Quigley, E. M. M., Treangen, T. J., Piskorz, M. M., & Villapol, S. (2025). Gut Microbiome dysbiosis and immune activation correlate with somatic and neuropsychiatric symptoms in COVID-19 patients. Journal of Translational Medicine, 23(1). https://doi.org/10.1186/s12967-025-06348-y

Vancouver

Scalzo PL, Marshall AG, Soriano S, Curry K, Dulay M, Hodics T, et al. Gut Microbiome dysbiosis and immune activation correlate with somatic and neuropsychiatric symptoms in COVID-19 patients. Journal of Translational Medicine. 2025;23(1). doi:10.1186/s12967-025-06348-y

BibTeX
@article{Scalzo2025,
  author = {Scalzo, Paula L and Marshall, Austin G and Soriano, Sirena and Curry, Kristen and Dulay, Mario and Hodics, Timea and Quigley, Eamonn M M and Treangen, Todd J and Piskorz, María M and Villapol, Sonia},
  title = {Gut Microbiome dysbiosis and immune activation correlate with somatic and neuropsychiatric symptoms in COVID-19 patients},
  journal = {Journal of Translational Medicine},
  year = {2025},
  volume = {23},
  number = {1},
  doi = {10.1186/s12967-025-06348-y}
}
Kostenlos starten →